Clinical trials: Dyslipidemia
Healthy, Hypercholesterolemia
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
This is a Phase 1, open-label, single-dose, randomized, dose escalation study in healthy and hypercholesterolemic subjects. Each subject will receive 1 of 5 treatments as a single subcutaneous injection.
- Trial name
- NCT02667223
- Testing
- Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypercholesterolemia
Effect of the Food Supplement TOTUM-070 on Lipid Metabolism
This clinical trial is to confirm the effects of TOTUM-070, a mix of 5 plants extracts, consumed at the daily regimen of two times per day, on fasting blood LDL cholesterol concentrations in moderately hypercholesterolemic…
- Trial name
- HEARTII (NCT06243484)
- Testing
- TOTUM-070
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Hypercholesterolemia, Cardiovascular Risk Factor
The Effect of Psyllium Fibre on LDL-C, Non-HDL-C, and Apolioprotein-B: A Systematic Review and Meta-analysis
Serum cholesterol is a major modifiable risk factor for cardiovascular disease, which despite considerable reduction in prevalence, remains the leading cause of premature mortality worldwide.
- Trial name
- NCT03346733
- Testing
- Psyllium Fibre
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Dyslipidemia
A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease
This is a double-blind, randomized study designed to compare the efficacy and safety of two fixed combinations of fenofibrate / simvastatin 145/20 mg and fenofibrate / simvastatin 145/40 mg tablets vs.
- Trial name
- NCT01674712
- Testing
- Fixed Combination of Fenofibrate/simvastatin 145/20 mg, Simvastatin 20 mg, Fenofibrate 145 mg
- Where
- 69 sites in Argentina, Czechia and 5 more
- Volunteers
- 575 people
- Sponsor
- Abbott
Obesity, Hypercholesterolemia
Improving the Management of Obesity in Primary Care Practice (The Power-UP Trial)
The purpose of the study is to compare three methods of achieving weight loss in primary care medical practice. The study will be conducted in six primary care practices.
- Conditions
- Obesity, Hypercholesterolemia, Metabolic Syndrome, Hypertension
- Trial name
- Power-UP (NCT00826774)
- Testing
- Usual Care, Brief Lifestyle Counseling, Enhanced Brief Lifestyle Counseling
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Dyslipidemia, High Risk Coronary Artery Disease
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)
The primary objective was to evaluate the effect of treatment with evolocumab on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever…
- Trial name
- FORWARD (NCT04087915)
- Testing
- Evolocumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Beijing Anzhen Hospital
Dyslipidemia, Atherosclerosis
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
The purpose of this study is to investigate an oral formulation of RVX000222 for safety, pharmacokinetic and efficacy in healthy subjects.
- Conditions
- Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
- Trial name
- NCT00768274
- Testing
- RVX000222
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Resverlogix Corp
Hyperlipidemias
The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism
The findings of previous experiments suggested that polyunsaturated fatty acids(PUFAs) has been linked to anti-hyperlipidemia, and reducing the risk of cardiovascular disease.This is a randomized double-blind trial, aims to study…
- Trial name
- PUFA (NCT03484988)
- Testing
- Echium oil, Mixed oil
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Huazhong University of Science and Technology
Hyperlipidemia
Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials
- Trial name
- NCT06471218
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Familial Hypercholesterolaemia, Hypercholesterolaemia
Specified Drug-use Survey of Leqvio for s.c. Injection.
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
- Trial name
- NCT06275724
- Testing
- inclisiran
- Where
- 107 sites in Japan
- Volunteers
- 585 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases, Hyperlipidemias
The Mixed Meal Challenge Study
The purpose of this study is to assess sample collection conditions for various dietary challenges (fat, sugar, and mixed) and determine the optimal fasting and post-meal sample collection time points for future studies on a…
- Trial name
- NCT05087823
- Testing
- Lipid Challenge, Glucose Challenge, Mixed Meal Challenge
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Emory University
Familial Hypercholesterolemia
Clinical Exploration Trial of YOLT-101 in the Treatment of Familial Hypercholesterolemia (FH)
This study is a single arm, open, single dose escalation trial aimed at evaluating the safety and tolerability of YOLT-101 administration in patients with familial hypercholesterolemia; Determination of YOLT-101 OBD; Preliminary…
- Trial name
- NCT06458010
- Testing
- YOLT-101
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Cardiovascular Risk Factors, Insulin Resistance
Pilot Validation of the STELA Preventive Medicine Platform to Reduce Modifiable Health Risk Factors in Adults (CPM-STELA)
This study evaluates a comprehensive digital health platform called STELA, developed at the Center for Preventive Medicine (CPM) of AGEL Hospital Trinec-Podlesi in Czechia.
- Conditions
- Cardiovascular Risk Factors, Insulin Resistance, Obesity, Dyslipidemias
- Trial name
- CPM-STELA (NCT07551960)
- Testing
- STELA Digital Preventive Medicine Platform, Comprehensive Preventive Health Assessment
- Where
- Czechia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nemocnice AGEL Trinec-Podlesi a.s.
Type 2 Diabetes, Dyslipidemia
The Effect of Type 2 Diabetes and Dietary Regulation on VLDL1-and VLDL2-triglyceride Metabolism
In this study the investigators wish to compare Very Low-Density Lipoprotein (VLDL) kinetics in type 2 diabetic males and healthy males postabsorptive and during hyperinsulinemia.
- Trial name
- NCT01564550
- Testing
- Insulin, diet, no diet
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Hypercholesterolemia
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)
Both simvastatin 40 mg and simvastatin/ezetimibe 10/10 mg result in low-density lipoprotein cholesterol (LDL-C) reductions of approximately the same magnitude.
- Trial name
- NCT00932620
- Testing
- SIMVASTATIN 40 mg, SIMVASTATIN/EZETIMIBE 10/10 mg
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Ioannina
Diabetes Mellitus
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286468
- Testing
- Alogliptin and glyburide, Glyburide
- Where
- 68 sites in United States, Argentina and 13 more
- Volunteers
- 500 people
- Sponsor
- Takeda
Hypertension, Dyslipidemias
To Evaluate the Pharmacokinetic/Pharmacodynamic Interactions and Safety Between ID1801 and ID1803 in Healthy Male Adults
This study is designated to evaluate the pharmacokinetic interactions of valsartan, amlodipine besylate, rosuvastatin, and ezetimibe in healthy male volunteers.
- Trial name
- NCT04185090
- Testing
- ID1803, ID1801, ID1803+ID1801
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
Insulinemic Response, Type 2 Diabetes (Adult Onset)
Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in Bogotá
This randomized clinical trial aims to evaluate the effects of refined high-oleic palm oil consumption on cardiovascular risk biomarkers and insulin resistance in healthy adults.
- Conditions
- Insulinemic Response, Type 2 Diabetes (Adult Onset), Hyperglycaemia (Diabetic), Hyperlipidaemia
- Trial name
- EDCHOPA-CRB (NCT07748559)
- Testing
- High-oleic palm oil
- Where
- Colombia
- Volunteers
- 52 people
- Sponsor
- Ruby Alejandra Villamil
Dyslipidemia/Glucose Metabolism Disorder
Acceptability of a Fixed Combination of Fenofibrate and Metformin
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
- Trial name
- NCT00348725
- Testing
- fenofibrate and metformin fixed combination (drug)
- Where
- 25 sites in France
- Volunteers
- 69 people
- Sponsor
- Solvay Pharmaceuticals
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer